Sandoz bags European Commission approval for biosimilar Tyruko for multiple sclerosis Ruchika Sharma26 Sept 2023 12:30 PM ISTBasel: Sandoz has announced that the European Commission (EC) has granted marketing authorization for the first and only biosimilar Tyruko...
Sandoz gets EMA Committee positive opinion for breast, gastric cancer biosimilar trastuzumab Ruchika Sharma19 Sept 2023 12:30 PM ISTBasel: Sandoz has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a...
Sandoz gets exclusive rights to commercialize biosimilar SB17 ustekinumab in US, Canada, EEA, Switzerland and UK Ruchika Sharma11 Sept 2023 1:30 PM ISTThe reference medicine Stelara (ustekinumab) is a monoclonal antibody medication to interleukin (IL)-12/23 for the treatment of autoimmune disorders...
Sandoz concludes acquisition of antifungal agent Mycamine from Astellas Ruchika Sharma28 Aug 2023 5:40 PM ISTBasel: Sandoz has successfully completed the acquisition of worldwide brand rights for systemic antifungal agent Mycamine (micafungin sodium, Funguard...
Sandoz bags USFDA approval for biosimilar Tyruko for relapsing forms of multiple sclerosis Ruchika Sharma26 Aug 2023 11:00 AM ISTTyruko has the same intravenous dosage form, route of administration, dosing regimen and presentation as the reference medicine.
Sandoz releases positive results from Mylight Phase lll study for biosimilar Aflibercept Ruchika Sharma16 Aug 2023 3:00 PM ISTAflibercept is a recombinant fusion protein that binds to vascular endothelial growth factor A and placental growth factor (PlGF), inhibiting abnormal...
Sandoz plans to build Biosimilar Technical Development Center in Slovenia Ruchika Sharma20 July 2023 3:30 PM ISTBasel: Sandoz has announced an investment of approximately USD 90 million at its site in Ljubljana, Slovenia to establish a dedicated Sandoz Biopharma...
Sandoz to move to new central Basel headquarters after spinoff Ruchika Sharma4 Jun 2023 10:00 AM ISTThe move into the new office building will not impact the management of the Sandoz global business.
EMA accepts marketing authorization applications for proposed biosimilar Denosumab: Sandoz Ruchika Sharma28 May 2023 10:00 AM ISTDenosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone...
New Sandoz Board of Directors appointed Ruchika Sharma15 May 2023 2:57 PM ISTBasel: The Novartis Board of Directors has approved the recommendations of the Sandoz Chairman-designate, Gilbert Ghostine, on the structure of the...
Sandoz strengthens pipeline expansion through partnership to develop, manufacture multiple biosimilars Ruchika Sharma10 May 2023 3:30 PM ISTBasel: Sandoz has announced a multi-year partnership with Just - Evotec Biologics, the Seattle-based subsidiary of Evotec SE. The agreement covers the...
Novartis division Sandoz to exclusively commercialize six products in US across key therapeutic areas Ruchika Sharma4 May 2023 5:40 PM ISTBasel: Sandoz has announced that it has signed a distribution and collaboration agreement with Adalvo for exclusive Sandoz rights to commercialize six...
